Lab tests using cisplatin, doxorubicin, cyclophosphamide (4HC), and docetaxel against breast tumors showed that cisplatin was most effective against triple negative cancers. In research presented at the 2009 Breast Cancer Symposium of the American Society of Clinical Oncologists:
• ER- breast cancer is more sensitive to cisplatin than ER+ breast cancer.
• Her2- is slightly more sensitive than Her2+
• ER- /Her2- breast cancer is more sensitive than ER-/Her2+.
So, if you add up the negatives, that means that triple negative gets a special boost from cisplatin.
Researchers also noted that breast tumors defined as “poorly-differentiated” are more sensitive to cisplatin than moderate and well- differentiated tumors
The researchers’ conclusion: “Cisplatin is the most active of the four tested drugs in TNBC.”